[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,84,96,145,167,191,216,245,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":43,"locationsCount":46},"100054328","pelvic-floor-muscle-training-and-dynamic-neuromuscular-stabilization-exercises-in-pediatric-patients-100054328",false,"NCT07267364","Pelvic Floor Muscle Training and Dynamic Neuromuscular Stabilization Exercises in Pediatric Patients","Effects of Adding Dynamic Neuromuscular Stabilization to Pelvic Floor Muscle Training on Voiding Dysfunction in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Having been diagnosed with voiding dysfunction according to ICCS diagnostic criteria in a urology outpatient clinic,\n* Being 5-18 years old,\n* The child and their parent\u002Fguardian agree to participate in the study voluntarily and provide signed consent.\n\nExclusion Criteria:\n\n* Organic pathologies such as urethral obstruction, ectopic ureter, spinal dysraphism, and diabetes\n* Diagnosis of VUR or neurogenic bladder\n* Cognitive and mental impairment\n* Having spina bifida\n* Being under 5 years of age\n* Receiving treatment such as PTC training or electrical stimulation",true,"ALL","5 Years","18 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","Dysfunctional voiding (DY) is one of the most common conditions in children. Various treatments are available. Participants will be randomly assigned to either PFMT (Group I) or PFMT+DNS (Group II). PFMT is the gold standard and routinely administered in hospitals for children diagnosed with dysfunctional voiding who are referred by a urologist. The PFMT group serves as the control group, and treatment will be scheduled for a total of 10 weeks, three days a week. During PFMT, children receive instruction about the pelvic floor using video visuals and increase awareness of their pelvic floor muscles. They are then instructed on how to contract and relax their muscles to control urination. DNS training is an exercise model that begins with spinal stabilization and addresses muscle synergies. Patients included in the study will be evaluated twice, at the beginning and at the end of the treatment: Voiding Disorders Symptom Score (VODS), Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0), Pediatric Incontinence Questionnaire (PIN-Q), Bladder Bowel Dysfunction Scale (BDS), Bristol gaita scale, and Children's Body Image Scale.",[28,29],"Urology","Pediatric Disorder",[31,32,33,34],"Voiding dysfunction","pelvic floor muscle training","neuromuscular stabilization","quality of life","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2025-11-11",{"date":36,"type":22},{"name":44,"class":45},"Necmettin Erbakan University","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681","NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","17 Years",{"count":57,"type":22},40,[59],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[29,62,63,64,65,66,67,68],"Genetic Predisposition","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[70,71,64,72,73],"Pediatric","Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","2026-06-19",{"date":76,"type":39},"2026-06-24",{"date":78,"type":39},"2024-10-15",{"date":80,"type":22},"2029-12-31",{"name":82,"class":45},"Children's Mercy Hospital Kansas City",1,{"id":85,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":26,"conditions":88,"keywords":89,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":95,"locationsCount":46},"100613497",{"count":21,"type":22},[25],[28,29],[31,32,33,34],"2026-04-30",{"date":92,"type":39},"2026-05-04",{"date":41,"type":39},{"date":90,"type":22},{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":18,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":83},"100466506","hereditary-spastic-paraplegia-genomic-sequencing-initiative-hspseq-100466506","NCT05354622","Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)","Investigating the Genetic Basis of Hereditary Spastic Paraplegia","Inclusion Criteria:\n\n* Clinical diagnosis of progressive spasticity","1 Month","30 Years",{"count":106,"type":22},200,"OBSERVATIONAL","The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.\n\nIn childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.",[110,111,29,112,113,114],"Hereditary Spastic Paraplegia","Neurodegenerative Diseases","Spasticity, Muscle","Motor Neuron Disease","Movement Disorders",[110,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135],"Neurodegenerative disease","Spasticity","SPG3a","SPG4","SPG11","SPG15","SPG26","SPG47","SPG50","SPG51","SPG52","Complex hereditary spastic paraplegia","Early Onset hereditary spastic paraplegia","Movement disorder","Adaptor protein complex 4","Neurogenetic disorder","Genetic Disease","Muscle Spasticity","Neurodevelopmental disorders","Musculoskeletal Disease","2026-03-16",{"date":138,"type":39},"2026-03-18",{"date":140,"type":39},"2022-04-25",{"date":142,"type":22},"2027-04-29",{"name":144,"class":45},"Boston Children's Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":83},"100561031","bedside-ultrasound-on-the-effectiveness-of-lumbar-puncture-in-children-100561031","NCT06584864","Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children.","Bedside Ultrasound on the Effectiveness of Lumbar Puncture in Children - Open-label Randomized Trial","Inclusion Criteria:\n\n* children \\\u003C18 years of age\n* patients who are scheduled to undergo lumbar puncture\n* consent of legal guardian\n\nExclusion Criteria:\n\n* infection of skin and tissues in the area of planned puncture\n* developmental defects of the spine and spinal cord\n* lack of consent of legal guardian\n* contraindications to lumbar puncture",{"count":153,"type":22},120,[25],"The aim of the study is to assess the influence of ultrasound examination of the lumbar spinal canal on the effectiveness of lumbar puncture. An open-label, randomized interventional study.",[157,29],"Meningitis","2025-07-29",{"date":160,"type":39},"2025-07-30",{"date":162,"type":39},"2024-03-01",{"date":164,"type":22},"2026-06-01",{"name":166,"class":45},"Medical University of Warsaw",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":83},"100496836","vaccinations-and-people-with-disabilities-100496836","NCT05749419","Vaccinations and People With Disabilities","Questionnaires and Focus Groups Based Quantitative & Qualitative Study of Vaccine Hesitancy and Confidence Among At-risk and Marginalized Populations: Persons With Special Needs, Intellectual Disabilities and Congenital Anomalies","Inclusion Criteria:\n\n• Diagnosed children with disabilities, chronic diseases or congenital anomalies\n\nExclusion Criteria:\n\n* Undiagnosed children\n* Inadequate filled out questionnaires",{"count":175,"type":22},1000,"The goal of this observational study is to learn about vaccinations hesitancy, delay or avoidance in children with chronic diseases, congenital anomalies or disabilities. The main questions it aims to answer are:\n\n• Attitudes of caregivers towards vaccinating their children, obstacles that postpone vaccinations, and the status of vaccinations of these children.\n\nParticipants will fill out questionnaires and some will be included in focused groups for the qualitative part of the study.\n\nResearchers will compare the vaccinations status of the research group to their siblings' status as well as the published national records of vaccination compliance.",[178,179,180,181,29],"Vaccine Refusal","Compliance, Patient","Disability, Intellectual","Congenital Disorders","2025-04-01",{"date":184,"type":39},"2025-04-03",{"date":186,"type":39},"2023-07-01",{"date":188,"type":22},"2026-01",{"name":190,"class":45},"Hadassah Medical Organization",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":199,"maxAge":19,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":46},"100462972","pediatric-liver-transplantation-liver-fibrosis-evaluation-by-using-fibrosis-panel-100462972","NCT05308628","Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel","Effect of the Fibrosis Panel on the Evaluation of Allograft Fibrosis After Pediatric Liver Transplantation","PT-LiFE","Inclusion Criteria:\n\n* Male or female participant must be between 8 weeks and 18 years of age.\n* Participant is a recipient of a first liver allograft from cadaveric or living donors.\n* Participant is a single-organ recipient (liver only).\n* Participants' parent\u002Fguardian is capable of understanding the purposes and risks of the study and must sign an informed consent for the study.\n\nExclusion Criteria:\n\n* Participants older than 18 years of age\n* Pregnant or breastfeeding\n* Active systemic infections\n* Receiving any form of solid organ retransplantation\n* Multiorgan transplantation\n* Multi organ failure\n* Congenital sufferers from heart, lung, kidney, nervous system or blood disease\n* Refused to participate the study","2 Months",{"count":201,"type":22},1200,[25],"Liver transplantation in children is highly successful with \\>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation (\"idiopathic\" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.",[205,29,206],"Liver Fibrosis","Liver Transplant; Complications","2024-08-05",{"date":209,"type":39},"2024-08-07",{"date":211,"type":39},"2022-04-30",{"date":213,"type":22},"2025-11-30",{"name":215,"class":45},"RenJi Hospital",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":232,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":83},"100555591","role-of-topical-steroid-injection-with-refractory-benign-esophageal-stricture-endoscopic-dilatation-in-children-100555591","NCT06514079","Role of Topical Steroid Injection With Refractory Benign Esophageal Stricture Endoscopic Dilatation in Children","ISIs","Inclusion Criteria:\n\n* Pediatric patients aged less than 14 years\n* with refractory benign esophageal strictures\n* received a dilatation therapy without triamcinolone injections\n\nExclusion Criteria:\n\n* failure to pass a guide wire secondary to pharyngeal stenosis\n* tracheo-esophageal fistula\n* those who received triamcinolone injections at early dilatation","2 Years","14 Years",{"count":226,"type":22},21,[25],"This clinical trial study included 21 children with refractory benign esophageal strictures. Upper GI endoscopy performed up to the area of stricture, esophageal dilatation done, endoscopy repeated, and steroid injected intralesional under direct endoscopic vision. The effect of the procedure was followed over a period of 12 months by evaluation of number of dilatation, maximum dilator size, periodic dilatation index (PDI) and dysphagia score.",[29,230,231],"Esophageal Diseases","Esophageal Stricture",[233,234,235],"Esophageal stricture","Steroid injection","Esophageal dilatation","2024-07-22",{"date":238,"type":39},"2024-07-23",{"date":240,"type":39},"2022-03-02",{"date":242,"type":22},"2024-08-20",{"name":244,"class":45},"Mohammad Daboos",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":19,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":263,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":83},"100554904","phase-4-comparing-the-difference-in-pain-control-in-the-pediatric-general-surgery-population-to-alternate-or-combine-acetaminophen-and-ibuprofen-100554904","NCT06505148","Comparing the Difference in Pain Control in the Pediatric General Surgery Population: to Alternate or Combine Acetaminophen and Ibuprofen?","Inclusion Criteria:\n\n* Age group: 3 years to 18 years\n* General surgery service (hernia, appendectomy, chole, circumcision, wounds, vacs, implanted central line, etc.)\n\nExclusion Criteria:\n\n* Patients who are allergic to acetaminophen and\u002For ibuprofen\n* Patients being evaluated by SANE or evaluated for nonaccidental trauma\n* Patients admitted post-op\n\nThe study will take place at McLane Children's Hospital Temple Market. Patients who are pregnant.","3 Years",{"count":253,"type":22},80,[255],"PHASE4","To examine the difference in pain control in the pediatric general surgery population alternating acetaminophen and Ibuprofen q 3 hours vs giving them simultaneous combination therapy around the clock.",[29],[259,260,261,262],"non opioid","pain management","pediatric pain","pediatric pain management","NOT_YET_RECRUITING","2024-07-18",{"date":236,"type":39},{"date":267,"type":22},"2024-08-01",{"date":269,"type":22},"2025-08-01",{"name":271,"class":45},"Baylor Research Institute",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":16,"sex":17,"minAge":278,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":46},"100551797","laryngomalacia-examinations-and-quality-of-life-in-children-before-and-after-treatment-with-follow-up-after-1-year-100551797","NCT06464757","Laryngomalacia, Examinations and Quality of Life in Children Before and After Treatment With Follow-up After 1 Year","Inclusion Criteria:\n\n* laryngomalacia\n* stridor\n* breathing difficulties\n\nExclusion Criteria:\n\n\\- none","1 Week","52 Weeks",{"count":281,"type":22},50,"Laryngomalacia is the most frequent cause of stridor in children under 1 year. The airway obstruction generates turbulent airway flow and creates the characteristic high-frequency stridor sound. In addition, the airway obstruction can cause apnea, a following drop in oxygen saturation and sleep disturbances. The symptoms of laryngomalacia are often worsened by activity, feeding, crying and lying flat on the back. The diagnosis is made with flexible laryngoscopy when the child is awake. The children are most often treated with expectation, information and guidance, observation with help with feeding and reflux treatment. Up to 20% of patients have a severe degree of laryngomalacia with apneas, which is an indication for surgical treatment. The investigators want to examine whether sleep examinations can help us deciding which child benefit from surgery, and follow-up the child again after 4-6 weeks and 1 year. The sleep examinations are carried out with polygraphy and\u002For polysomnography with simultaneous audio records and video monitoring and with Somnofy from VitalThings. The investigators want to use artificial intelligence and machine learning when analyzing the sleep examinations. The investigators also want to have a control group examining the sleep and breathing during night at home. In both groups the investigators want to examine the quality of life with the questionnaire ITQoL-SF47.",[284,285,286,287,29,288,289],"Laryngomalacia","Sleep Apnea, Obstructive","Sleep Apnea","Ear, Nose and Throat Disorder","Surgery","Quality of Life","2024-06-17",{"date":292,"type":39},"2024-06-18",{"date":294,"type":39},"2024-01-01",{"date":296,"type":22},"2034-12-31",{"name":298,"class":45},"Oslo University Hospital"]